In contrast, a group of 344 patients with high-risk early ER+/HER2− BC treated with nivolumab + NAChT patients with ≥1% sTILs had a greater rate of pCR than patients with sTILs < 1% [48]. This evidence concerns the gene ESR1 and breast cancer.